Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders.
Salivary glands (SGs) exhibit several important features which are also common to endocrine glands: self-containment due to a surrounding capsule, highly efficient protein production and the ability to secrete proteins into the bloodstream. We have hypothesized that SGs are potentially useful as gene transfer targets for the correction of inherited monogenetic endocrine disorders. In the present communication, we extend our studies and attempt to test our hypothesis by comparing the efficacy of two commonly used viral vectors and the resulting serum and salivary distribution of transgene encoded hormones. A low dose (5 x10(9) particles) of either an adenoviral serotype 5 (Ad5) vector encoding the human erythropoietin (hEPO) cDNA or an adeno-associated virus sero-type 2 (AAV2) vector encoding either the hEPO or human growth hormone (hGH) cDNA was administered to individual submandibular SGs of Balb/c mice. Serum and salivary hEPO and hGH levels were determined at defined time points. Two additional recombinant viruses encoding enhanced green fluorescence protein (GFP) were also used (AdGFP and AAVGFP) in order to perform immunohistochemical analyses of transgenic protein localization in SG sections post-administration. AAV2 vectors led to stable gene transfer unlike the results with the Ad5 vectors. Indeed, in one mouse we observed hEPO production for a period of two years after administration of AAVhEPO to SGs. hEPO, which is a constitutive pathway secretory protein, was readily secreted into the bloodstream from the SGs, yielding therapeutically adequate serum levels. Conversely, hGH, a regulated secretory pathway protein, was preferentially secreted into saliva. SGs may be an attractive candidate target tissue for gene therapeutics of some monogenetic endocrine deficiency disorders. At present, AAV2 vectors seem particularly useful for such applications, and transgenes encoding constitutive secretory pathway hormones are more suitable for this application with SGs than those encoding regulated secretory pathway hormones.
Voutetakis
Antonis
A
Gene Therapy and Therapeutics Branch, NIDCR, NIH, DHHS, Bethesda, Maryland 20892, USA.
Bossis
Ioannis
I
Kok
Marc R
MR
Zhang
Weitian
W
Wang
Jianghua
J
Cotrim
Ana P
AP
Zheng
Changyu
C
Chiorini
John A
JA
Nieman
Lynnette K
LK
Baum
Bruce J
BJ
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000229:Dependovirus / Q000235:genetics; D004921:Erythropoietin / Q000097:blood / Q000172:deficiency* / Q000235:genetics; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage; D049452:Green Fluorescent Proteins / Q000235:genetics; D020249:Hormone Replacement Therapy / Q000379:methods*; D019382:Human Growth Hormone / Q000032:analysis / Q000172:deficiency* / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D051379:Mice; D008807:Mice, Inbred BALB C; D008856:Microscopy, Fluorescence; D012463:Saliva / Q000737:chemistry; D013363:Submandibular Gland / Q000378:metabolism*; D014161:Transduction, Genetic / Q000379:methods; D019076:Transgenes
D004921:Erythropoietin; D019382:Human Growth Hormone; D049452:Green Fluorescent Proteins